Dysken M W, Mendels J, LeWitt P, Reisberg B, Pomara N, Wood J, Skare S, Fakouhi J D, Herting R L
GRECC Program, Minneapolis VAMC, MN 55417.
J Am Geriatr Soc. 1992 May;40(5):503-6. doi: 10.1111/j.1532-5415.1992.tb02019.x.
Milacemide, a MAO-B inhibitor that is also a prodrug for glycine, was tested as a treatment for senile dementia of the Alzheimer type (SDAT) because of its potential for enhancing cognition in animal models of impaired learning and memory.
Double-blind, placebo-controlled, randomized clinical trial.
Sixteen study sites, both university-affiliated and private.
A total of 228 outpatients (116 men and 112 women) with SDAT, ranging in age from 49-93 years.
1200 mg/day milacemide treatment for 1 month (113 patients received milacemide, and 115 patients received placebo).
Alzheimer's Disease Assessment Scale and the Mini-Mental State Examination.
Milacemide-treated SDAT patients did not show significant improvement in any of the outcome measures used. Significant elevations in liver enzymes in four subjects were of sufficient magnitude to necessitate withdrawal from the study.
Milacemide does not appear to be an effective treatment in enhancing cognition in SDAT patients.
米拉醋胺是一种单胺氧化酶B抑制剂，也是甘氨酸的前体药物，因其在学习和记忆受损动物模型中具有增强认知的潜力，故被作为阿尔茨海默型老年痴呆症（SDAT）的一种治疗方法进行测试。
双盲、安慰剂对照、随机临床试验。
16个研究地点，包括大学附属医院和私立机构。
总共228例SDAT门诊患者（116名男性和112名女性），年龄在49至93岁之间。
每天1200毫克米拉醋胺治疗1个月（113例患者接受米拉醋胺治疗，115例患者接受安慰剂治疗）。
阿尔茨海默病评估量表和简易精神状态检查表。
接受米拉醋胺治疗的SDAT患者在任何所使用的观察指标上均未显示出显著改善。4名受试者的肝酶显著升高，幅度足以使其退出研究。
米拉醋胺似乎不是增强SDAT患者认知的有效治疗方法。
